AdAlta Ltd. (AU:1AD) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AdAlta Limited is gearing up for clinical activities with strategic appointments and partnerships. The company has secured a non-binding term sheet for its AdCella unit and aims to advance its AD-214 drug candidate for fibrotic diseases. AdAlta’s bolstered leadership and improved cash position signal promising progress in their ‘East to West’ cellular immunotherapy strategy.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.